In summary, in our cohort, undetectable ctDNA after 6–8 weeks of therapy and high baseline levels of MCP1 and TNFα are all individual predictors of superior PFS in metastatic melanoma patients treated with first-line checkpoint inhibitors. The gene discussed is CCL2; the disease is metastatic melanoma.